The common cold is one of our most widespread diseases today. In the Nordic countries, with a combined population of around 25 million, there are 75 million incidents of the common cold every year according to the Swedish Institute for Communicable Disease Control. The potential market for a new medical treatment of the common cold is, not surprisingly, tremendous.
Swedish biotechnology company Enzymatica AB has developed a new, easy-to-use and effective treatment for the common cold based on patented enzyme technology. The treatment, ColdZyme Mouth spray, has recently been launched in Sweden and is currently sold in pharmacies and supporting stores across the country.
Successful market introduction
The market introduction was made possible through a registration of the product as a Medical Device class 1. The product immediately gained high level interest with several newspapers and magazines writing articles about this new and revolutionary invention. This in combination with the many professional Swedish athletes and clubs using the product to stay healthy and reach peak performances helped the successful market introduction.
Second face of launch with much visibility in TV and other media will be commenced during autumn when the cold season once again will make its entrance.
ColdZyme Mouth spray will be launched for sale in the rest of the Nordic countries in 2014. Enzymatica estimates the potential market in the Nordic region at around 25 million infections, which is equivalent to one-third of the incidence of the common cold treated with some form of medical preparation today. The market is also expected to increase steadily each year by around five per cent, according to data presented by Euromonitor/IMS.
Further development
ColdZyme Mouth spray is intended to be used to prevent colds, but it can also shorten the duration of the disease if the spray is used from an early stage of the infection. One of the ingredients in the mouth spray is an enzyme from deep-sea cod, which has proven to have very good therapeutic qualities.
So far, the focus of Enzymatica has largely been on developing in-depth knowledge of the common cold and how it can be treated. The enzyme used in ColdZyme will be used in the development of other medical treatments at Enzymatica focusing on upper airway infections, oral infections and inflammations, as well as in dermatology.
In addition to the mouth spray, the ColdZyme brand also comprises of a medical chewing gum which, if used daily, can reduce the risk of tooth decay and cavities. This product is already widely available in Sweden.
Aiming for NASDAQ OMX
Enzymatica is currently listed on the Aktietorget stock exchange. Michael Edelborg Christensen announced earlier this year that the company is planning to change lists and has decided to begin the process of listing on NASDAQ OMX Stockholm Stock Exchange during the first six months of 2014.
“The listing on the Stockholm Stock is central to Enzymatica’s international expansion. The successful launch of the ColdZyme range, in combination with a growing market and our exclusive expertise in the field, are all positive pointers to a continuously bright future for the company,” Edelborg Christensen concludes.
